Akili Interactive Labs

Akili Interactive Labs specializes in developing prescription therapies using video games to target mental conditions such as attention deficit hyperactivity disorder (ADHD), anxiety, bipolar disorder, and depression. By merging neuroscience with interactive gaming, the company aims to actively engage users and stimulate specific cognitive neural systems in the brain. Its flagship product, EndeavorRx, is an FDA-cleared prescription treatment designed for children aged 8 to 12 with ADHD. Akili is the first game-based therapeutic to receive FDA approval for any condition and the first digital therapeutic approved for ADHD. In June 2020, the company obtained approval to offer its product in Europe, expanding its reach to a broader audience.

In June 2023, Akili unveiled EndeavorOTC, an over-the-counter (OTC) iteration of its FDA-approved digital therapeutic software, originally available only by prescription. This OTC version is tailored for adults dealing with ADHD and does not require a doctor's prescription. In September 2023, Akili announced its plans to focus on a D2C business model and transition away from its prescription-based approach.

In August 2022, the firm completed its merger with Social Capital Suvretta Holdings Corp. (SCS), a special purpose acquisition company (SPAC), resulting in a combined entity listed on Nasdaq as "AKLI". The merger was valued at USD 1 billion and generated USD 163 million in gross proceeds. For FY2023, the company reported a non-GAAP net loss of USD 59.5 million, a 35% decrease YoY.

Key customers and partnerships

In March 2019, Akili partnered with Shionogi to commercialize Akili’s digital medicines in Japan and Taiwan. Further, in August 2021, Akili Interactive Labs licensed TALi Digital's technology to develop a new game-based treatment for improving early childhood attention. In May 2022, Akili agreed to a partnership with global gaming platform Roblox , allowing children using EndeavorRx for ADHD treatment to redeem rewards on the platform.